Reuters
"Fonterra, however, told Reuters that it had not yet received any such notice from the FDA itself.
An FDA spokesperson told Reuters in an email response that the FDA had sent letters to some firms, not all, deferring further reviews of applications due to a list of issues.
"For firms that received letters, they do not mean that the infant formulas are unsafe; rather, they indicate that we have found issues that would unlikely be resolved quickly," the spokesperson said.
Deferral is not rejection! This looks like a pause whilst they clean house, page-25
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$7.95 |
Change
0.150(1.92%) |
Mkt cap ! $5.770B | |||
| Open | High | Low | Value | Volume |
| $7.87 | $7.99 | $7.71 | $13.44M | 1.720M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 5011 | $7.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.96 | 1294 | 4 |
View Market Depth
| Last trade - 15.56pm 27/06/2025 (20 minute delay) ? |
| A2M (ASX) Chart |